It is a controversial treatment, but the results have been promising for some patients with post-traumatic stress disorder.
Now, a new treatment for PTSD could help combat a painful condition that can result in post-partum depression and anxiety.
“What we’re trying to do is make it possible for patients to feel that there is no more trauma,” said Dr. Mark Shulman, the clinical director of the Center for Clinical Research in Posttraumatic Stress Disorder (CPRD), at Yale University.
Shulman says his team at Yale has been studying the effects of azo-derived compounds for treating PTSD for more than a decade.
They’ve found that combining one compound with another can significantly reduce symptoms.
“One compound is an antidepressant.
One compound is a cognitive enhancer,” he said.
Shumman’s group is studying compounds that have been tested in animals and humans.
The goal is to find compounds that can be used safely and effectively to treat PTSD patients, while also increasing their self-esteem.
The compound they are testing is called riluzole, which is a synthetic version of the amino acid rilocin.
“Riluzoles have been found to increase cognition in animals.
The same is true for humans,” said Shulmann.
The compounds they are using are derived from the amino acids racemic and dioxyprogesterone, and they’re not as effective in humans as they are in animals, but they are safe and effective in a wide range of conditions, including PTSD, which affects 1 in 100 people.
The research is funded by the National Institutes of Health and the National Institute of Neurological Disorders and Stroke.
The new treatment is based on a drug called rofecoxib, which has shown promise in the past.
It works by decreasing brain dopamine levels in the brain.
It also reduces the levels of an enzyme called cyclooxygenase-2, which helps the body make oxygen and other molecules.
The compound has also shown promise for treating symptoms of PTSD in people with depression and panic disorder.
“We’re really excited about this new compound because it can actually reduce the effects that are causing the symptoms,” said Amy Avila, one of the lead researchers on the study.
The researchers found that rofevoxib reduced symptoms of anxiety in the rats tested, but not in humans.
The effects on depression and PTSD symptoms were similar in both groups of animals, though the researchers found no effect on anxiety levels in people.
“In terms of efficacy, we were not surprised that the compounds were safe and not dangerous,” Avilo said.
A similar compound, known as fosamprenavir, has also been tested on animals.
It’s also been used to treat people with anxiety disorders, but has not been found effective.
“There is an enormous amount of research that’s gone into the use of opioids in the treatment of PTSD,” said Aviloa.
“We’ve seen a lot of promising results with the drugs in PTSD.”